• Farid Ljuca, Bahrudin Hadžiefendić, Elmir Jahić, Nijaz Tihić, and Saša Lukić.
• Department of Physiology, School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina. E-mail. farid.ljuca@untz.ba.
• Saudi Med J. 2019 Dec 1; 40 (12): 1202-1208.

ObjectivesTo assess the prognostic value of pentraxin 3 (PTX3) in patients with ST-elevation myocardial infarction (STEMI) after bare-metal stent (BMS) implantation.MethodsIn this prospective study, PTX3, interleukin (IL-6), IL-10, high-sensitivity c-reactive protein  (hsCRP), and cardiac troponin I (cTnI) plasma values were determined before and 24 hours after BMS implantation in 97 consecutively enrolled patients with STEMI who were admitted to University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina between February 2016 and February 2017. Patients were followed for 24 months to assess major adverse cardiovascular events (MACEs).ResultsAt 24 hours after percutaneous coronary intervention (PCI), plasma values of  PTX3, IL-6, hsCRP, and cTnI were significantly increased; and IL-10 levels were significantly decreased compared with the values determined before PCI. Patients with MACEs had significantly higher plasma PTX3 levels at 24 hours after BMS-PCI than in patients without MACEs. Patients with PTX3 plasma values ≥5042 ng/ml had a significantly higher risk of MACEs than patients with PTX3 levels <5.042 ng/mL. Pentraxin 3 levels exhibited strong and significant correlations with IL-6 and IL-10 levels. Pentraxin 3, cTnI, and IL-6, but not hsCRP levels have showed independent association with MACEs, according to the multivariate Cox regression analysis.ConclusionPentraxin 3 might be better serum prognostic marker than IL-6, IL-10 or high sensitivity CRP for MACEs after BMS-PCI. It might help to make better risk stratification of those patients who are undergoing BMS-PCI.

20 keywords...

hide…